Long-term results after surgical resection of intrahepatic cholangiocarcinoma before and since the BILCAP era - Takeaways - MDSpire

Long-term results after surgical resection of intrahepatic cholangiocarcinoma before and since the BILCAP era

  • By

  • Fabian Bartsch

  • Constantin Scholz

  • Lisa-Katharina Gröger

  • Lara Bachmann

  • Janine Baumgart

  • Ann-Kathrin Lederer

  • Jens Mittler

  • Maria Hoppe-Lotichius

  • Beate K. Straub

  • Friedrich Foerster

  • Arndt Weinmann

  • Evangelos Tagkalos

  • Hauke Lang

  • June 10, 2026

  • 0 min

Share

  • 1

    Capecitabine became the standard adjuvant treatment for intrahepatic cholangiocarcinoma following the BILCAP trial results presented in 2017.

  • 2

    This study analyzed 334 patients who underwent surgical resection of intrahepatic cholangiocarcinoma from 2008 to 2023.

  • 3

    After propensity score matching, the post-BILCAP group showed significantly better time to recurrence and recurrence-free survival compared to the pre-BILCAP group.

  • 4

    Median overall survival was 20.5 months for the pre-BILCAP group and 29.1 months for the post-BILCAP group, but the difference was not statistically significant.

  • 5

    The study concludes that while capecitabine may not significantly improve overall survival, it positively influences time to recurrence and recurrence-free survival.

Original Source(s)

Related Content